Developments in the Screening and Prognostication of Melanoma

Video

This peer-to-peer discussion reviews the current strategies for managing patients with melanoma, including screening and prognosis for high-risk patients and how to choose the best therapies to avoid toxicities and treatment resistance.

In this peer-to-peer discussion, Ahmad A. Tarhini, MD, PhD, of the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, and Sancy Leachman, MD, PhD, of the Oregon Health & Science University (OHSU) Knight Cancer Institute in Portland, review the current strategies for managing patients with melanoma, including screening and prognosis for high-risk patients and how to choose the best therapies to avoid toxicities and treatment resistance.

Tarhini and Leachman spoke at an education session on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

 

Recent Videos
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content